title: Diabetic state-induced activation of calcium-activated neutral proteinase in mouse skeletal muscle.
abstract: The effect of a diabetic state in the diabetic KK-CAy mouse on calcium activated neutral proteinase (CANP) of hind-limb skeletal muscles was investigated. In the diabetic state, there was an increased sensitivity to activation of CANP by calcium (Ca). In addition, there was an enhancement of maximal activity of the enzyme. The effect was induced by secondary modification of the diabetic state, but not genetical factors. Several lines of evidence suggest that the CANP is responsible for 92 K dalton protein in diabetic skeletal muscles. Among the evidence are the following: a) The 92 K band in the diabetic muscles was lower than in the prediabetic mouse and restored by the addition of 2 mM EDTA and 2 mM EGTA. b) The band was reduced by increasing the Ca content and neutral pH in the non-diabetic normal muscles. c) E-64-C, a CANP inhibitor, restored the 92 K component reduced by the diabetic state. Since the band in denervated muscles was not changed by the Ca chelating agents, the reduction of the band in the diabetic muscles is related with musculotrophic factors, not diabetic neuropathy. These results suggest that diabetic amyotrophy may be regarded as a phenomenon linked to an increase in intracellular Ca ions and an increase in CANP activity.
authors.affiliation: Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Fujihara
authors.forename: N
authors.initials: N
authors.lastname: Hoshino
authors.forename: I
authors.initials: I
authors.lastname: Kimura
authors.forename: M
authors.initials: M
authors.lastname: Kimura
mesh_terms: D000185:Actinin / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000494:pharmacology; D002154:Calpain / Q000378:metabolism*; D002462:Cell Membrane / Q000201:enzymology; D003402:Creatine Kinase / Q000032:analysis / Q000502:physiology; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology*; D004492:Edetic Acid / Q000494:pharmacology; D004533:Egtazic Acid / Q000494:pharmacology; D004586:Electrophoresis; D004789:Enzyme Activation; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D051379:Mice; D009132:Muscles / Q000201:enzymology*
chemical_list: D015853:Cysteine Proteinase Inhibitors; D000185:Actinin; D004533:Egtazic Acid; C032425:N-(N-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine; D004492:Edetic Acid; D003402:Creatine Kinase; D002154:Calpain; D007930:Leucine; D002118:Calcium